Early HCC: Diagnosis and molecular markers

Journal of Gastroenterology

Volumn 44, Issue SUPPL. 19, 2009, Pages 108-111

  Sakamoto, Michiie ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

CAP2; GPC3; Hepatocellular carcinoma; HSP70

Indexed keywords

CYCLASE ASSOCIATED PROTEIN 2; GLUTAMATE AMMONIA LIGASE; GLYPICAN 3; HEAT SHOCK PROTEIN 70; MOLECULAR MARKER; ONCOPROTEIN; PROTEIN CAP2; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CHRONIC LIVER DISEASE; CLINICAL FEATURE; DISEASE COURSE; EARLY CANCER; EARLY DIAGNOSIS; GENE EXPRESSION; GENE MUTATION; HEPATITIS B; HEPATITIS C; HISTOPATHOLOGY; HUMAN; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; ONCOGENE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CARCINOMA, HEPATOCELLULAR; GLUTAMATE-AMMONIA LIGASE; GLYPICANS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LIVER NEOPLASMS; MEMBRANE PROTEINS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 58849087179     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-008-2245-y     Document Type: Article

References (20)

1. Arakawa M, Kage M, Sugihara S, Nakashima T, Suenaga M, Okuda K. Emergence of malignant lesions within an adenomatous hyperplastic nodule in a cirrhotic liver. Observations in five cases. Gastroenterology 1986;91:198-208.
2. Tsuda H, Hirohashi S, Shimamoto Y, Terada M, Hasegawa H. Clonal origin of atypical adenomatous hyperplasia of the liver and clonal identity with hepatocellular carcinoma. Gastroenterology 1988;95:1664-1666.
3. Takayama T, Makuuchi M, Hirohashi S, Sakaomoto M, Okazaki N, Takayasu K, et al. Malignant transformation of adenomatous hyperplasia to hepatocellular carcinoma. Lancet 1990;336:1150-1153.
4. Sakamoto M, Hirohashi S, Shimamoto Y. Early stages of multi-step hepatocarcinogenesis: Adenomatous hyperplasia and early hepatocellular carcinoma. Hum Pathol 1991;22:172-178.
5. Hirohashi S, Ishak KG, Kojiro M, Puig PL, Wanless IR, Fischer HP, et al. Hepatocellular carcinoma. In: Hamilton SR, Aaltonen LA, editors. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. p. 159-172.
6. Kojiro M. Pathology of hepatocellular carcinoma. Oxford: Blackwell; 2006.
7. Matsui O, Kadoya M, Kameyama T, Yoshikawa J, Takashima T, Nakanuma Y, Unoura M, et al. Benign and malignant nodules in cirrhotic livers: distinction based on blood supply. Radiology 1991;178:493-497.
8. Kudo M. Morphological diagnosis of hepatocellular carcinoma: Special emphasis on intranodular hemodynamic imaging. Hepatogastroenterology 1998;45:1226-1231.
9. Takayama T, Makuuchi M, Hirohashi S, Sakamoto M, Yamamoto J, Shimada K, et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 1998;28:1241-1246.
10. Sakamoto M, Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: Multiinstitutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 1998;28:604-608.
11. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, Hirohashi S. Expression profiling in multistage hepatocarcinogenesis: Identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 2003;37:198-207.
12. Shibata R, Mori T, Du W, Chuma M, Gotoh M, Shimazu M, et al. Overexpression of cyclase-associated protein 2 in multistage hepatocarcinogenesis. Clin Cancer Res 2006;12(18):5363-5368.
13. Fedor-Chaiken M, Deschenes RJ, Broach JR. SRV2, a gene required for RAS activation of adenylate cyclase in yeast. Cell 1990;61:329-340.
14. Baum B, Li W, Perrimon N. A cyclase-associated protein regulates actin and cell polarity during Drosophila oogenesis and in yeast. Curr Biol 2000;10:964-973.
15. Capurro M, Wanless IR, Sherman M, Deboer G, Shi W, Miyoshi E, Filmus J. Glypican-3: A novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003;125(1):89-97.
16. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, et al. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun 2003;306(1):16-25.
17. Hippo Y, Watanabe K, Watanabe A, Midorikawa Y, Yamamoto S, Ihara S, et al. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004;64(7):2418-2423.
18. Osada T, Sakamoto M, Nagawa H, Yamamoto J, Matsuno Y, Iwamatsu A, et al. Acquisition of glutamine synthetase expression in human hepatocarcinogenesis: Relation to disease recurrence and possible regulation by ubiquitin-dependent proteolysis. Cancer (Phila) 1999;85(4):819-831.
19. Cadoret A, Ovejero C, Terris B, Souil E, Lévy L, Lamers WH, Kitajewski J, et al. New targets of beta-catenin signaling in the liver are involved in the glutamine metabolism. Oncogene 2002;21(54):8293-8301.
20. Di Tommaso L, Franchi G, Park YN, Fiamengo B, Destro A, Morenghi E, et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis. Hepatology 2007;45(3):725-734.